Physician profile
Felix M Ramirez
NPI 1538149836
$2,150.05
in general payments reported to CMS, 2019-2025
32 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $202 · 2021: $315 · 2022: $530 · 2023: $352 · 2024: $192 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $362.30 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $301.40 | 2019-2023 | Xtampza |
| Stryker Corporation | $202.00 | 2019 | |
| Si-Bone, INC. | $141.61 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $113.71 | 2022 | |
| Boston Scientific Corporation | $112.14 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Almatica Pharma LLC | $110.73 | 2022-2023 | Loreev Xr, Gralise |
| Redhill Biopharma INC. | $87.82 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.83 | 2020-2023 | Relistor |
| Virtus Pharmaceuticals LLC | $56.12 | 2021 | |
| Protega Pharmaceutials INC | $54.58 | 2025 | Roxybond |
| Forte Bio-Pharma LLC | $51.68 | 2022 | |
| Masimo Corporation | $47.32 | 2023-2024 | Patient Safetynet System |
| Tersera Therapeutics LLC | $41.56 | 2019 | |
| Bioventus LLC | $40.91 | 2019-2025 | Xcell |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $32.84 | 2022 | |
| Zyla Life Sciences, INC. | $32.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $30.66 | 2022 | |
| Abbvie INC. | $25.62 | 2023 | |
| Medtronic USA, INC. | $24.33 | 2019 | |
| Fidia Pharma USA INC. | $23.72 | 2021 | |
| Pacira Therapeutics, INC. | $21.90 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.37 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $19.45 | 2021 | |
| Valinor Pharma, LLC | $17.80 | 2024 | Movantik |
| Astrazeneca Pharmaceuticals LP | $16.50 | 2019 | |
| Lilly USA, LLC | $16.41 | 2021 | |
| Nevro Corp. | $15.35 | 2022 | |
| Novo Nordisk INC | $14.39 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $13.73 | 2024 | |
| Hikma Pharmaceuticals USA | $12.04 | 2021 | |
| Electronic Waveform Lab, INC. | $7.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.